Navigation Links
Alexza Reports 2012 Second Quarter Financial Results and Provides Business Update
Date:8/8/2012

MOUNTAIN VIEW, Calif., Aug. 8, 2012 /PRNewswire/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today reported financial results for the fiscal quarter ended June 30, 2012 and provided a business update.  The net loss for the quarters ended June 30, 2012 and 2011, as reported in accordance with accounting principles generally accepted in the United States (GAAP), were $7.0 million and $9.0 million, respectively.  The net loss for the six-month periods ended June 30, 2012 and 2011 were $10.8 million and $17.4 million, respectively.  At June 30, 2012, Alexza had consolidated cash, cash equivalents, marketable securities and restricted cash of $26.4 million.

"Since our last quarterly update in May, we have made strong progress with both of our ADASUVE™ marketing applications, resulting in the resubmission of our ADASUVE NDA and the Day 120 Response for our ADASUVE MAA," said Thomas B. King, President and CEO of Alexza.  "We also completed the EU Pre-Approval Inspection of our Mountain View facility.  We now have our NDA PDUFA date in December 2012 and also project our Day 210 opinion from the CHMP for our MAA in December of this year.

King continued, "We have also established a committed equity financing facility with Azimuth Opportunity, L.P., replacing a similar facility that expired in June.  This new financing facility provides Alexza additional financing flexibility by giving us the potential ability to raise capital efficiently."

Alexza Business Update

The following key events, in chronological order, occurred since the beginning of the second quarter of 2012:

  • In May, Alexza received a second Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its ADASUVE New Drug Application (NDA).  In June, Alexza resubmitted its ADASUVE NDA to the FDA in response
    '/>"/>

  • SOURCE Alexza Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related medicine technology :

    1. Alexza Announces Management Promotions
    2. Alexza Secures a $20 Million Committed Equity Financing Facility with Azimuth Opportunity, L.P.
    3. Alexza Announces Reverse Stock Split in Order to Maintain NASDAQ Listing
    4. Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Alexza Pharmaceuticals Inc.
    5. Alexza Receives Complete Response Letter for Adasuve™ NDA
    6. Alexza to Announce 2012 First Quarter Financial Results on Thursday, May 10, 2012
    7. NxStage Reports Record Revenue For The Second Quarter Of Fiscal 2012
    8. InfuSystem Holdings, Inc. Reports $14.1 Million of Revenues for the Second Quarter of 2012; Announces Annualized Cost Savings in Excess of $1 million
    9. diaDexus, Inc. Reports Second Quarter 2012 Financial Results
    10. HeartWare Reports Second Quarter 2012 Results
    11. Omeros Corporation Reports Second Quarter 2012 Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/31/2015)... 2015  Asterias Biotherapeutics, Inc. (NYSE MKT: AST), ... of regenerative medicine, today announced that the third ... -based Rush University Medical Center in a ... doses of AST-OPC1 (oligodendrocyte progenitor cells) in newly ... spinal cord injury (SCI). This represents the final ...
    (Date:8/31/2015)... N.J. and STAMFORD, Conn. ... pharmaceutical subsidiary of Eisai Co., Ltd., and Purdue Pharma ... worldwide collaboration agreement for the development and commercialization of ... orexin receptor antagonist entering Phase III clinical development for ... terms of the agreement, Eisai and Purdue Pharma will ...
    (Date:8/31/2015)... , Aug. 31, 2015 Bionomics Limited ... and development of innovative therapeutics for the treatment of ... today announced that its BNC101 IND submission has passed ... Bionomics plans to initiate a Phase 1 clinical trial ... with metastatic pancreatic cancer prior to 31 December 2015. ...
    Breaking Medicine Technology:Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 4Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 5Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 6Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 2Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 3Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 4Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 5Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 2Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 3Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 4
    ... multiple sclerosis, remained relapse-free after three years of treatment ... active brain lesions - the ... - MS, a devastating disease causing progressive disability, affects 2.5 ... including many young adults - FTY720 regulatory filings planned before ...
    ... basis of methotrexate,resistance and differences in methotrexate response, ... analysis,of the genetic determinants of resistance to the ... could offer a,pathway to predicting such resistance and ... Children,s Research Hospital study., Besides its use ...
    Cached Medicine Technology:FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 2FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 3FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 4FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 5FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 6St. Jude Gene Study Reveals Basis of Anti-Cancer Drug Resistance in Childhood Leukemia 2St. Jude Gene Study Reveals Basis of Anti-Cancer Drug Resistance in Childhood Leukemia 3St. Jude Gene Study Reveals Basis of Anti-Cancer Drug Resistance in Childhood Leukemia 4
    (Date:8/31/2015)... ... August 31, 2015 , ... The 2015 New ... patients and family members, medical professionals, and researchers, covering a variety of topics ... is a collaborative effort between the Mesothelioma Applied Research Foundation and ...
    (Date:8/31/2015)... ... August 31, 2015 , ... Coast Dental Vista is celebrating ... 11 a.m. to 3 p.m. near Albertsons in the Foothill Center, located at 1279 ... Ofelia Rivera and Dr. Jay Lopp. Call (760) 208-2518 for more details or stop ...
    (Date:8/31/2015)... ... September 01, 2015 , ... Neuropsychiatric ... injury with emphasis on transcranial near-infrared laser phototherapy ”. , As corresponding author ... has been largely untreatable - with mostly palliative treatments only - and now ...
    (Date:8/31/2015)... ... August 31, 2015 , ... NJ Top Docs Presents, Dr. Michael Betsy! Dr. Betsy ... Ridge, New Jersey, Dr. Michael Betsy graduated from Don Bosco Prep in 1990 and was ... team captain in both sports in his senior year. He was inducted into the ...
    (Date:8/31/2015)... , ... August 31, 2015 , ... ... makers, diagnostic services, and others—to hold down costs? , In a commentary for ... officer of HealthReveal, presents the concept of “clinical efficacy,” which would bind parties ...
    Breaking Medicine News(10 mins):Health News:New York Experts on Mesothelioma Come Together at Memorial Sloan Kettering Cancer Center 2Health News:New York Experts on Mesothelioma Come Together at Memorial Sloan Kettering Cancer Center 3Health News:Discover How to Replace Missing Teeth, Reduce Cavities, and Restore Oral Health During Coast Dental’s Open House in Vista, CA on Sept. 5, 2015 2Health News:Discover How to Replace Missing Teeth, Reduce Cavities, and Restore Oral Health During Coast Dental’s Open House in Vista, CA on Sept. 5, 2015 3Health News:Near-Infrared Laser Phototherapy for Brain Injury published by Dove Medical Press 2Health News:Near-Infrared Laser Phototherapy for Brain Injury published by Dove Medical Press 3Health News:NJ Top Docs Presents, Dr. Michael Betsy! 2Health News:NJ Top Docs Presents, Dr. Michael Betsy! 3Health News:How “Clinical Efficacy” Can Rein in Healthcare Costs 2Health News:How “Clinical Efficacy” Can Rein in Healthcare Costs 3
    ... be saved every year, thanks to a simple online calculator ... having ovarian cancer at a much earlier stage. Academics ... a new QCancer algorithm using the UK QResearch database. The ... factors to red flag those most likely to have ovarian ...
    ... (HealthDay News) --Families hoping to improve their fitness and overall ... TV or computer screen and more time being active together, according ... the following tips to help your family get moving and stay ... Stroll together after a family meal or walk around the mall ...
    ... The current issue of Medical Acupuncture , a ... how the U.S. military is incorporating medical acupuncture to ... in the war zones and the efforts underway to ... online at http://www.liebertpub.com/acu . "The use of ...
    ... press release is available in French . ... liver during digestion, has been seriously underestimated. A study published ... kill several types of cancer cells, such as those found ... research team, led by Concordia University, included scientists from McGill ...
    ... bowel disease (IBD) are increasing with time and in ... study in Gastroenterology , the official journal of ... worldwide epidemiology of inflammatory bowel disease is important for ... Gilaad G. Kaplan, MD, MPH, of the University of ...
    ... substances in licorice used extensively in Chinese traditional medicine ... and gum disease, the leading causes of tooth loss in ... of Natural Products , they say that these substances could ... gum disease. Stefan Gafner and colleagues explain that ...
    Cached Medicine News:Health News:Simple online tool to aid GPs in early ovarian cancer diagnosis 2Health News:Simple online tool to aid GPs in early ovarian cancer diagnosis 3Health News:Cancer-killing compound spares healthy cells 2Health News:IBD emerges as a global disease 2
    The Atria 6100 delivers the highest level of clinical performance while incorporating cutting-edge technology to streamline clinic workflow. It offers timely, high-quality, and accurate ECG results c...
    The CSV-1000ETDRS10% test face presents the standard ETDRS test at a contrast level of 10%. This test is widely used in clinical studies for the evaluation of refractive surgery and contact lenses....
    The CSV-1000SLanC test face provides the same tests as the standard CSV-1000S, except that the acuity test is presented in Landolt C format. , ,This test is very useful when testing patients who cann...
    ... CSV-1000E contrast sensitivity chart test face is the ... world. This test provides for four (4) rows ... of 8 ft (2.5 meters), these gratings test ... 18 cycles/degree. The CSV-1000E provides a full contrast ...
    Medicine Products: